Molecular imaging and therapy developer Aposense has signed a material transfer agreement with the University of Pittsburgh.
The institution will use the vendor's EarliTest apoptosis imaging technology in a clinical trial in patients with glioblastoma multiforme brain cancer. Aposense will receive deidentified clinical data from the trial, which will be funded by the U.S. National Institutes of Health (NIH).
